导管原位癌局部区域治疗后的疾病特异性生存结局:观察性队列研究
该研究基于美国1330个中心2008—2014年确诊的纯导管原位癌女性分层随机样本,比较单纯保乳手术、保乳手术加放疗与全乳切除术后的生存结局。
要点
- 三种局部治疗方案8年疾病特异性生存率均≥99.6%,组间无显著差异。
- 单纯保乳手术较保乳加放疗总生存较低(HR 1.29,95%CI 1.00–1.67)。
- 该总生存差异在<65岁亚组仍存在(HR 1.86,95%CI 1.15–3.00)。
核心结论
- 导管原位癌患者接受单纯保乳手术、保乳手术加放疗或全乳切除术,疾病特异性生存无统计学显著差异。
- 鉴于疾病特异性死亡绝对风险低,可个体化选择局部区域治疗而不必担心损害生存。
研究设计与样本
- 观察性队列研究,从美国1330个中心分层随机抽取2008—2014年确诊的纯导管原位癌患者。
- 采用抽样权重与重叠权重结合,估计三种治疗方式的人群平均边际疾病特异性生存和总生存。
主要发现
- 共35例女性死于乳腺癌,死亡时中位年龄62岁(四分位距50—74)。
- 所有治疗组8年疾病特异性生存率均≥99.6%,组间无显著差异:单纯保乳手术对比保乳加放疗HR 1.19(95%CI 0.29—4.85);全乳切除术对比保乳加放疗HR 1.74(95%CI 0.53—5.72)。
- 全乳切除术与保乳加放疗的总生存无差异(HR 1.09,95%CI 0.83—1.43)。
- 单纯保乳手术较保乳加放疗总生存较低(HR 1.29,95%CI 1.00—1.67),该差异除<65岁亚组(HR 1.86,95%CI 1.15—3.00)外其余亚组均消失。
临床怎么用
- 与患者讨论局部治疗方案时,可告知三种方案疾病特异性生存结局相近,支持个体化决策。
- 对接受单纯保乳手术的患者,尤其<65岁者,应关注总生存差异并个体化评估放疗指征。
局限性
- 为观察性队列研究,治疗分组非随机,可能存在残余混杂。
- 乳腺癌死亡事件数少(35例),亚组分析及组间比较的置信区间较宽。
- 随访中位67.8个月,尚不足以评估更长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast-conserving surgery alone, breast-conserving surgery with adjuvant radiation treatment, and mastectomy are guideline-concordant treatments for ductal carcinoma in situ. The aim of this study was to compare survival outcomes between these treatment options. METHODS: A stratified random sample of patients diagnosed with pure ductal carcinoma in situ between 2008 and 2014 was selected from 1330 sites in the USA. Data on diagnosis, treatment, and follow-up were abstracted by local cancer registrars. Population-averaged marginal estimates of disease-specific survival and overall survival for breast-conserving surgery alone, breast-conserving surgery with radiation treatment, and mastectomy were obtained by combining sampling and overlap weights. RESULTS: A total of 18 442 women were included, with a median follow-up of 67.8 (interquartile range 46.1-93.5) months. A total of 35 women died from breast cancer, at a median age of 62 (interquartile range 50-74) years. Population-averaged 8-year rates of disease-specific survival were 99.6% or higher for all treatment groups, with no significant differences between groups (breast-conserving surgery alone versus breast-conserving surgery with radiation treatment, HR 1.19 (95% c.i. 0.29 to 4.85); and mastectomy versus breast-conserving surgery with radiation treatment, HR 1.74 (95% c.i. 0.53 to 5.72). There was no difference in overall survival between the patients who underwent a mastectomy and the patients who underwent breast-conserving surgery with radiation treatment (HR 1.09 (95% c.i. 0.83 to 1.43)). Patients who underwent breast-conserving surgery alone had lower overall survival compared with the patients who underwent breast-conserving surgery with radiation treatment (HR 1.29 (95% c.i. 1.00 to 1.67)). This survival difference vanished for all but one subgroup, namely patients less than 65 years (HR 1.86 (95% c.i. 1.15 to 3.00)). CONCLUSION: There was no statistically significant difference in disease-specific survival between women operated with breast-conserving surgery alone, breast-conserving surgery with radiation treatment, or mastectomy for ductal carcinoma in situ. Given the low absolute risk of disease-specific mortality, these results provide confidence in offering individualized locoregional treatment without fear of compromising survival.
引用
- Wang SM, Li Y, Nash A, et al. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. Br J Surg. 2024. PMID: 39213131. doi:10.1093/bjs/znae198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。